FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Telomere Stack

Anti-Aging & Longevityintermediate

79

상호작용

79
Share
펩타이드

2

일 평균 mcg

10,500

수준

intermediate

추가됨

May 17, 2026

개요

The Telomere Stack is a focused two-peptide protocol targeting chromosomal maintenance and cellular rejuvenation. Epithalon''s primary mechanism is activation of the catalytic subunit of telomerase (hTERT), the enzyme responsible for adding TTAGGG repeats to chromosome ends. In cell culture studies, Epithalon-treated fibroblasts showed a 33% increase in telomere length and extended their replicative lifespan by approximately 10 additional cell divisions beyond the Hayflick limit. In Khavinson''s longitudinal human studies, elderly patients receiving Epithalon showed normalized melatonin production, improved immune markers, and reduced all-cause mortality compared to controls over 6-12 year follow-up periods. GHK-Cu contributes to this stack through its remarkable gene expression modulation profile. Genome-wide studies reveal that GHK-Cu resets expression of numerous aging-related genes toward youthful patterns, including genes involved in DNA repair (GADD45A, XRCC1), antioxidant defense (SOD3, glutathione peroxidase), and anti-inflammatory pathways (IL-6 suppression, TGF-beta modulation). This transcriptomic "resetting" effect complements Epithalon''s telomere maintenance by ensuring that cells with preserved telomere length also maintain youthful functional capacity rather than persisting in a senescent-adjacent state. The stack follows a cyclical protocol: Epithalon is administered daily for 10 days, then discontinued for 4-6 months while GHK-Cu continues daily. This cycling is based on Khavinson''s research showing that telomerase activation occurs during the treatment window and persists for months afterward, making continuous administration unnecessary. GHK-Cu provides ongoing cellular maintenance between Epithalon cycles. This is one of the more conservative longevity stacks, suitable for individuals who want to address cellular aging biomarkers with well-characterized peptides.

용량 프로토콜

Epithalon

daily (10-day cycle)· subcutaneous

Epithalon에 대한 자세한 내용 →

10,000 mcg

1회 용량당

GHK-Cu

Every day· subcutaneous

GHK-Cu에 대한 자세한 내용 →

500 mcg

1회 용량당

목표 및 증거

Telomere extensionCellular agingSkin healthDNA repairLongevity
증거 등급:동물 연구

경고

  • Epithalon was removed from the FDA Category 2 list (April 2026) but remains pending PCAC review (July 24, 2026) — not legal to compound yet. Telomere extension claims based on in-vitro and animal studies. Human longevity data is observational only.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.